|
Invasive carcinoma of breast
|
0.100 |
AlteredExpression
|
disease |
BEFREE |
Expression of CD74 in invasive breast carcinoma: its relation to Nottingham Prognostic Index, hormone receptors, and HER2 immunoprofile.
|
27834468 |
2017 |
|
Invasive carcinoma of breast
|
0.100 |
Biomarker
|
disease |
BEFREE |
<b>Methods:</b> We used Affymetrix GeneChips to analyze 365 primary human epidermal growth factor receptor 2 (HER2)-negative invasive breast cancer specimens.
|
28529618 |
2017 |
|
Invasive carcinoma of breast
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
Our study identified unique gene signatures in ERBB2-positive DCIS, which may be associated with the development of invasive breast carcinoma.
|
28178722 |
2017 |
|
Invasive carcinoma of breast
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
This randomized trial aimed to establish safety and evaluate immune and clinical responses to vaccination via intralesional (IL), intranodal (IN), or both intralesional and intranodal (ILN) injection.<b>Experimental Design:</b> Fifty-four HER2<sup>pos</sup> patients [42 pure ductal carcinoma <i>in situ</i> (DCIS), 12 early invasive breast cancer (IBC)] were enrolled in a neoadjuvant HER2 peptide-pulsed DC1 vaccine trial.
|
27965306 |
2017 |
|
Invasive carcinoma of breast
|
0.100 |
Biomarker
|
disease |
BEFREE |
The University of Texas MD Anderson Cancer Center database of HER2 dual-probe fluorescence in situ hybridization results from 2000 to 2010 was searched for cases of invasive breast cancer with HER2/CEP17 ratios < 2 and average HER2 copy numbers < 6 per cell.
|
27893937 |
2017 |
|
Invasive carcinoma of breast
|
0.100 |
Biomarker
|
disease |
BEFREE |
The overexpression of the oncogene human epidermal growth factor receptor 2 (HER-2) has been associated with decreased disease-free survival and is a marker of poor prognosis of invasive breast cancer.
|
29113154 |
2017 |
|
Invasive carcinoma of breast
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
Multivariable Cox proportional hazards regression models provided hazard rate ratios (HRR) for the association between NSAID use and risk of invasive breast cancer as well as hormone receptor- and HER2-defined subtypes.
|
28460643 |
2017 |
|
Invasive carcinoma of breast
|
0.100 |
AlteredExpression
|
disease |
BEFREE |
Our data shows that GRB7 expression in invasive breast cancer correlates with markers of a more aggressive phenotype, including HER2 overexpression, a greater degree of HER2 amplification, ER negativity, and p53 positivity.
|
26945445 |
2017 |
|
Invasive carcinoma of breast
|
0.100 |
Biomarker
|
disease |
BEFREE |
We demonstrated the utility of this assay in several applications including demonstration of the existence of a layer of normal myoepithelial KRT14 expressing cells that separate HER2+ cancer cells from the stromal and immune microenvironment in HER2+ invasive breast cancer.
|
29184166 |
2017 |
|
Invasive carcinoma of breast
|
0.100 |
Biomarker
|
disease |
BEFREE |
Since pCR portends long-term favorable outcomes, these results support additional clinical investigations using HER2-directed vaccines in combination with anti-estrogen treatments for ER<sup>pos</sup>/HER2<sup>pos</sup> DCIS and invasive breast cancer.
|
28932627 |
2017 |
|
Invasive carcinoma of breast
|
0.100 |
Biomarker
|
disease |
BEFREE |
We retrospectively reviewed patients with stages I-III HER2-positive invasive breast cancer who had definitive surgery in 1999-2015 and received neoadjuvant systemic therapy (NST).
|
28081544 |
2017 |
|
Invasive carcinoma of breast
|
0.100 |
Biomarker
|
disease |
BEFREE |
There is limited data on results of central re-testing of samples from patients with invasive breast cancer categorised in their local hospital laboratories as oestrogen receptor (ER) positive and human epidermal growth factor receptor homologue 2 (HER2) negative.
|
28222072 |
2017 |
|
Invasive carcinoma of breast
|
0.100 |
Biomarker
|
disease |
BEFREE |
Retrospective analysis of 1739 patients with invasive breast carcinoma who underwent reflex HER2 (fluorescence in situ hybridization [FISH]) testing, using both 2007 and 2013 guidelines (2007-2014).
|
28433541 |
2017 |
|
Invasive carcinoma of breast
|
0.100 |
AlteredExpression
|
disease |
BEFREE |
Similarly, human epidermal growth factor receptor 2 is more commonly overexpressed in ductal carcinoma in situ (∼27%-56%) when compared with invasive breast cancer (∼11%-20%).FGFR3mutations in bladder cancer also decrease with tumor grade (low-grade tumors, ∼61%; high-grade, ∼11%).
|
27059373 |
2016 |
|
Invasive carcinoma of breast
|
0.100 |
AlteredExpression
|
disease |
BEFREE |
Compared with Her-2-negative cases by D-FISH, Her-2 D-FISH-equivocal cases had higher Ki67 expression, higher histological grade, more frequent lymph node metastasis, and lower estrogen receptor α expression, indicating a group of BCa with worse prognosis.
|
27455837 |
2016 |
|
Invasive carcinoma of breast
|
0.100 |
Biomarker
|
disease |
BEFREE |
HER2 testing was performed by immunohistochemistry (IHC) and dual-color in situ hybridization (DISH) on surgical specimens from 50 patients with invasive breast cancer.DISH was evaluated by two methods.
|
24771412 |
2016 |
|
Invasive carcinoma of breast
|
0.100 |
Biomarker
|
disease |
BEFREE |
This case series involved consecutive patients diagnosed with invasive breast carcinoma with equivocal immunohistochemistry score and referred for further HER2 assessment from the departments of Surgery and/or Clinical Oncology of the two hospitals between January 2013 and February 2014.
|
26823385 |
2016 |
|
Invasive carcinoma of breast
|
0.100 |
Biomarker
|
disease |
BEFREE |
HER2 intratumoral heterogeneity analyses by concurrent HER2 gene and protein assessment for the prognosis of HER2 negative invasive breast cancer patients.
|
27318853 |
2016 |
|
Invasive carcinoma of breast
|
0.100 |
Biomarker
|
disease |
BEFREE |
In this study, using an immunohistochemical method, 272 patients with invasive breast cancer were assessed for the expression of CHIP (graded scores 0-3) and the statuses of biomarkers, such as estrogen receptor (ER), progesterone receptor (PgR), and HER2.
|
27334118 |
2016 |
|
Invasive carcinoma of breast
|
0.100 |
AlteredExpression
|
disease |
BEFREE |
The aim of this study was to evaluate over expression of HER2/neu in DCIS and cases of ADH in comparison with invasive breast carcinoma.
|
27644608 |
2016 |
|
Invasive carcinoma of breast
|
0.100 |
Biomarker
|
disease |
BEFREE |
We explored breast cancer susceptibility genes testing on ≤40-year-old patients with HER2-amplified invasive breast cancer.
|
26681682 |
2016 |
|
Invasive carcinoma of breast
|
0.100 |
Biomarker
|
disease |
BEFREE |
The aim of our study was to compare the estrogen receptor, progesterone receptor and HER2 status as determined by the MapQuant™ test to the routine immuno-histochemical tests in early stage invasive breast cancer in a large comprehensive cancer center.
|
26829108 |
2016 |
|
Invasive carcinoma of breast
|
0.100 |
AlteredExpression
|
disease |
BEFREE |
Prognostic contribution of mammographic breast density and HER2 overexpression to the Nottingham Prognostic Index in patients with invasive breast cancer.
|
27806715 |
2016 |
|
Invasive carcinoma of breast
|
0.100 |
AlteredExpression
|
disease |
BEFREE |
We explored the clinical utility of human epidermal growth factor receptor-2 extracellular domain (HER2/ECD) in patients treated for an invasive breast cancer with HER2 overexpression.
|
27709352 |
2016 |
|
Invasive carcinoma of breast
|
0.100 |
AlteredExpression
|
disease |
BEFREE |
Human epithelial growth factor receptor 2 (HER2) overexpression and/or amplification is of predictive and prognostic value in infiltrating breast carcinoma (IBC).
|
27097809 |
2016 |